Guobo Li

SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.

Yuquan Wei, Q. Lei, Yong Xia, 2014, Cancer letters.

YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models

Yuquan Wei, Xiaoyun Dai, Sheng-yong Yang, 2013, British journal of pharmacology.

A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Sheng-yong Yang, Luoting Yu, Wenjie Lu, 2015, BMC Cancer.

YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Yuquan Wei, You-Li Pan, Q. Lei, 2014, Scientific Reports.

Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073

Yuquan Wei, Cuicui Ma, Xiawei Wei, 2020, Antimicrobial Agents and Chemotherapy.

Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway

Yuquan Wei, Min Wu, Shirui Tan, 2015, Scientific Reports.